(secondQuint)Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections.

 100 patients with positive HPV-16 and HPV-18 infection are randomized into interferon gel group and control group at ratio of 1:1 (50 patients in treatment group and 50 patients in control group).

 The patients in treatment group received 1g recombinant human -2b interferon gel every other day for consecutive 6-10 courses of treatment, whereas no treatment was conducted in control group.

.

 Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections@highlight

to assess the efficacy and safety of recombinant human interferon -2b gel (Yallaferon(R)) for the treatment of patients with cervical HPV-16 and/or HPV-18 infections; to analyze the HPV type infections and clinical negative conversion.

